869 related articles for article (PubMed ID: 26165918)
21. The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children.
Voysey M; Kandasamy R; Yu LM; Baudin M; Sadorge C; Thomas S; John T; Pollard AJ
Vaccine; 2016 Jul; 34(35):4221-4228. PubMed ID: 27364096
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children.
Diez-Domingo J; Delgado JD; Ballester A; Baldó JM; Planelles MV; Garcés M; Graullera M; Ubeda MI; Sánchez F; Sánchez MM; Azor E; Cabrera A; López F; Alvarez M; San-Martín M; González A; Boisnard F; Thomas S
Pediatr Infect Dis J; 2005 Mar; 24(3):219-24. PubMed ID: 15750457
[TBL] [Abstract][Full Text] [Related]
23. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants.
Yeh SH; Ward JI; Partridge S; Marcy SM; Lee H; Jing J; Curry ES; Howe BJ
Pediatr Infect Dis J; 2001 Oct; 20(10):973-80. PubMed ID: 11642632
[TBL] [Abstract][Full Text] [Related]
25. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
27. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers.
Southern J; Andrews N; Burrage M; Miller E
Vaccine; 2005 May; 23(29):3829-35. PubMed ID: 15893621
[TBL] [Abstract][Full Text] [Related]
29. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
Aquino AG; Brito MG; Doniz CE; Herrera JF; Macias M; Zambrano B; Plennevaux E; Santos-Lima E
Vaccine; 2012 Oct; 30(45):6492-500. PubMed ID: 22863658
[TBL] [Abstract][Full Text] [Related]
30. Absence of a significant interaction between a Haemophilus influenzae conjugate vaccine combined with a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine in the same syringe and inactivated polio vaccine.
Daum RS; Zenko CE; Given GZ; Ballanco GA; Parikh H; Vidor E; Liu X
Pediatr Infect Dis J; 2000 Aug; 19(8):710-7. PubMed ID: 10959738
[TBL] [Abstract][Full Text] [Related]
31. Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose.
Liang J; Wallace G; Mootrey G
MMWR Morb Mortal Wkly Rep; 2015 Sep; 64(34):948-9. PubMed ID: 26334944
[TBL] [Abstract][Full Text] [Related]
32. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
Bégué PC; Grimprel EM; Giovannangeli MD; Abitbol VI
Pediatr Infect Dis J; 1998 Sep; 17(9):804-9. PubMed ID: 9779766
[TBL] [Abstract][Full Text] [Related]
33. Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV).
Okada K; Miyazaki C; Kino Y; Ozaki T; Hirose M; Ueda K
J Infect Dis; 2013 Jul; 208(2):275-83. PubMed ID: 23568174
[TBL] [Abstract][Full Text] [Related]
34. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
[TBL] [Abstract][Full Text] [Related]
35. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
[TBL] [Abstract][Full Text] [Related]
36. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age.
Vergara R; Tregnaghi M; Ussher J; Navarro S; Rüttimann R; Potin M; Wolter J; Schuerman L
Eur J Pediatr; 2005 Jun; 164(6):377-82. PubMed ID: 15782295
[TBL] [Abstract][Full Text] [Related]
37. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine.
Kitchin N; Southern J; Morris R; Borrow R; Fiquet A; Boisnard F; Thomas S; Miller E
Vaccine; 2009 Aug; 27(37):5096-102. PubMed ID: 19573637
[TBL] [Abstract][Full Text] [Related]
38. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
[TBL] [Abstract][Full Text] [Related]
39. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
[TBL] [Abstract][Full Text] [Related]
40. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
Chotpitayasunondh T; Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
